Axonis Therapeutics
PrivateLast Round
Series A
Oct 30, 2024
Total Funding Raised
$141.7M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Axonis Therapeutics is a biotechnology company developing first-in-class oral small molecule therapies targeting KCC2 to treat central nervous system disorders such as epilepsy, chronic pain, and spinal cord injuries.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Axonis Therapeutics Comparables
Compare Axonis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IAMA Therapeutics | 81% | |
| Leal Therapeutics | 80% | |
| NovaGo Therapeutics | 79% |
Axonis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 30, 2024 | ||||
| Grant | Sep 1, 2024 | ||||
| Seed | Jul 14, 2021 | ||||
| Seed | May 28, 2020 |
Key People
Founding team and executive leadership
Axonis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Biomedical Imaging and Bioengineering | Seed |
| Iaso Ventures | Series A |
| SCI Ventures | Series A |
| CURE Epilepsy | Grant |
| Perceptive Advisors | Series A |
| Acks | Series A |
| NIH RADx | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 44% MoM.
- Oct 15, 2025
Translating discoveries from Boston Children's Hospital, Harvard, and Laval University.
Axonis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Axonis Therapeutics's valuation, stock price, and market status.
Is AXONIS Therapeutics a public or private company?
AXONIS Therapeutics is a private company.
What is the current stock price of AXONIS Therapeutics?
AXONIS Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is AXONIS Therapeutics worth (valuation)?
Valuation information for AXONIS Therapeutics is not publicly available.
Can I buy AXONIS Therapeutics stock?
AXONIS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AXONIS Therapeutics's last funding round?
AXONIS Therapeutics's most recent funding round was Series A on October 30, 2024.
Who are the main investors in AXONIS Therapeutics?
Key investors in AXONIS Therapeutics include Alexandria Venture Investments, venBio, Cormorant Asset Management.
Will AXONIS Therapeutics IPO soon?
No public IPO plans have been announced for AXONIS Therapeutics.
How can I track AXONIS Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AXONIS Therapeutics's secondary market activity and sign up for updates.